Avantor Stock Forecast, Price & News

15 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Avantor in the last year. There are currently 15 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Avantor stock.
View analyst ratings for Avantor or view top-rated stocks.

Wall Street analysts have given Avantor a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Avantor wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Avantor is scheduled to release its next quarterly earnings announcement on Tuesday, October 26th 2021.
View our earnings forecast for Avantor.

Avantor, Inc. (NYSE:AVTR) issued its quarterly earnings results on Thursday, July, 29th. The company reported $0.35 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $0.30 by $0.05. The business earned $1.86 billion during the quarter, compared to analyst estimates of $1.73 billion. Avantor had a net margin of 4.47% and a trailing twelve-month return on equity of 44.55%.
View Avantor's earnings history.

Avantor's stock was trading at $12.92 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, AVTR shares have increased by 233.1% and is now trading at $43.04.
View which stocks have been most impacted by COVID-19.

15 analysts have issued 1-year target prices for Avantor's shares. Their forecasts range from $30.00 to $51.00. On average, they anticipate Avantor's stock price to reach $42.63 in the next year. This suggests that the stock has a possible downside of 1.0%.
View analysts' price targets for Avantor or view top-rated stocks among Wall Street analysts.

Some companies that are related to Avantor include Illumina (ILMN), Agilent Technologies (A), Mettler-Toledo International (MTD), Waters (WAT), Bio-Rad Laboratories (BIO.B), Bio-Rad Laboratories (BIO), PerkinElmer (PKI), 10x Genomics (TXG), Bruker (BRKR), Coherent (COHR), Pacific Biosciences of California (PACB), Cytek BioSciences (CTKB), Olink Holding AB (publ) (OLK), HORIBA (HRIBF) and Quanterix (QTRX).
View all of AVTR's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Avantor investors own include Honeywell International (HON), Johnson & Johnson (JNJ), NVIDIA (NVDA), The Procter & Gamble (PG), Raytheon Technologies (RTX), Alibaba Group (BABA), CVS Health (CVS), The Home Depot (HD), Pfizer (PFE) and QUALCOMM (QCOM).

(AVTR) raised $3 billion in an initial public offering on Friday, May 17th 2019. The company issued 154,000,000 shares at a price of $18.00-$21.00 per share. Goldman Sachs, J.P. Morgan, BofA Merrill Lynch, Barclays and Jefferies served as the underwriters for the IPO and Credit Suisse, Deutsche Bank Securities, Evercore ISI, Guggenheim Securities, Morgan Stanley, UBS Investment Bank, Citigroup, Cowen, Piper Jaffray, RBC Capital Markets, Baird, William Blair, Janney Montgomery Scott, KeyBanc Capital Markets, PJT Partners, Raymond James, Stephens, Stifel, SunTrust Robinson Humphrey, Wells Fargo Securities and Drexel Hamilton were co-managers.

Avantor trades on the New York Stock Exchange (NYSE) under the ticker symbol "AVTR."

Avantor's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Price T Rowe Associates Inc. MD (12.03%), Vanguard Group Inc. (8.33%), BlackRock Inc. (6.04%), Invesco Ltd. (4.86%), Boston Partners (3.64%) and American Century Companies Inc. (2.67%). Company insiders that own Avantor stock include Christi Shaw, Christophe Couturier, David D Petratis, Devashish Ohri, Frederic Vanderhaegen, Gerard Brophy, James Bramwell, Jo Natauri, Justin Miller, Michael Stubblefield, Michael Wondrasch, New Mountain Investments Iii,, Rajiv Gupta and Steven W Eck.
View institutional ownership trends for Avantor.

AVTR stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Schonfeld Strategic Advisors LLC, Invesco Ltd., BlackRock Inc., Twin Tree Management LP, American Century Companies Inc., Third Point LLC, and Magnetar Financial LLC. Company insiders that have sold Avantor company stock in the last year include Christi Shaw, Christophe Couturier, David D Petratis, Devashish Ohri, Frederic Vanderhaegen, Gerard Brophy, James Bramwell, Jo Natauri, Justin Miller, Michael Stubblefield, Michael Wondrasch, New Mountain Investments Iii,, Rajiv Gupta, and Steven W Eck.
View insider buying and selling activity for Avantor or view top insider-selling stocks.

AVTR stock was purchased by a variety of institutional investors in the last quarter, including Bessemer Group Inc., Boston Partners, State Street Corp, Victory Capital Management Inc., Vaughan Nelson Investment Management L.P., FMR LLC, Jupiter Asset Management Ltd., and Price T Rowe Associates Inc. MD.
View insider buying and selling activity for Avantor or or view top insider-buying stocks.

Shares of AVTR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AVTR stock can currently be purchased for approximately $43.04.

Avantor has a market capitalization of $25.14 billion and generates $6.39 billion in revenue each year. The company earns $116.60 million in net income (profit) each year or $0.89 on an earnings per share basis.

Avantor employs 12,400 workers across the globe.

The official website for Avantor is www.avantorsciences.com.

Avantor is headquartered at BUILDING ONE SUITE 200 100 MATSONFORD ROAD, RADNOR PA, 19087.

Avantor's mailing address is BUILDING ONE SUITE 200 100 MATSONFORD ROAD, RADNOR PA, 19087. The company can be reached via phone at (610) 386-1700 or via email at [email protected]